Literature DB >> 25755615

Staging of hepatocellular carcinoma.

Ajay Duseja1.   

Abstract

Hepatocellular carcinoma (HCC) is different from other malignancies because the prognosis in HCC is not only dependent upon the tumor stage but also on the liver function impairment due to accompanying cirrhosis liver. Various other staging systems used in HCC include the European systems [French staging system, Barcelona Clinic Liver Cancer (BCLC) staging system and the cancer of the liver Italian program (CLIP)] and Asian systems [Okuda staging system, Japan integrated Staging (JIS), Tokyo score and Chinese University Prognostic Index (CUPI)]. Out of all the staging systems used in HCC, Barcelona Clinic Liver Cancer (BCLC) staging system is probably the best because it takes in to account the tumor status (defined by tumor size and number, presence of vascular invasion and extrahepatic spread), liver function (defined either by the Child-Pugh's class) and general health status of the patient (defined by the ECOG classification and the presence of symptoms). Since most of the extrahepatic spread in HCC occurs to lymph nodes, lungs and bones, the assessment can be done with either PET/CT or a combination of CT (Chest and abdomen) and a bone scan. This article describes the various staging systems used in HCC, guides choosing a staging system particularly in the Indian context and the assessment of extra-hepatic spread in HCC.

Entities:  

Keywords:  AJCC, American Joint committee on cancer; BCLC; BCLC, Barcelona clinic liver cancer; CLIP, cancer of the liver Italian program; CUPI, Chinese University prognostic index; ES, extra-hepatic spread; HCC, hepatocellular carcinoma; ITDV, intra tumor vascular density; LCSGJ, liver cancer study group of Japan; OLT, orthotopic liver transplant; Okuda; TNM, tumor-node-metastasis; VEGF, vascular endothelial growth factor; hepatocellular carcinoma (HCC)

Year:  2014        PMID: 25755615      PMCID: PMC4284240          DOI: 10.1016/j.jceh.2014.03.045

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  26 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma.

Authors:  J M Llovet; J Bruix
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

3.  Clinical profile, etiology and therapeutic outcome in 324 hepatocellular carcinoma patients at a tertiary care center in India.

Authors:  Shashi B Paul; Sreenivasa Baba Chalamalasetty; Sreenivas Vishnubhatla; Kaushal Madan; Shivanand R Gamanagatti; Yogesh Batra; Siddhartha D Gupta; Subrat K Panda; Subrat K Acharya
Journal:  Oncology       Date:  2009-07-28       Impact factor: 2.935

4.  A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.

Authors:  S Chevret; J C Trinchet; D Mathieu; A A Rached; M Beaugrand; C Chastang
Journal:  J Hepatol       Date:  1999-07       Impact factor: 25.083

5.  Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto.

Authors:  I Levy; M Sherman
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

6.  Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.

Authors:  Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Mi Sung Park; Eun Hye Kim; Jinsil Seong; Do Youn Lee; Kwang-Hyub Han
Journal:  Liver Int       Date:  2012-04-23       Impact factor: 5.828

7.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design.

Authors:  Chiun Hsu; Ying-Chun Shen; Chia-Chi Cheng; Fu-Chang Hu; Ann-Lii Cheng
Journal:  Contemp Clin Trials       Date:  2009-09-06       Impact factor: 2.226

9.  Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score.

Authors:  Hobyung Chung; Masatoshi Kudo; Shunsuke Takahashi; Satoru Hagiwara; Yasuhiro Sakaguchi; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toyokazu Fukunaga; Takashi Matsunaga
Journal:  J Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 4.029

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  25 in total

Review 1.  Management before hepatectomy for hepatocellular carcinoma with cirrhosis.

Authors:  Hisashi Nakayama; Tadatoshi Takayama
Journal:  World J Hepatol       Date:  2015-09-18

2.  Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1α for hepatocellular carcinoma: a preliminary study of rat model.

Authors:  Jia-Yan Ni; Lin-Feng Xu; Wei-Dong Wang; Qiao-Sheng Huang; Hong-Liang Sun; Yao-Ting Chen
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-16       Impact factor: 4.553

3.  Hepatocellular metastasis recurrence in liver transplant after treatment with direct antiviral agents.

Authors:  Silvia Maier; Debora Donnini; Laura De Luca; Claudio Avellini; Leonardo Alberto Sechi; Giorgio Soardo
Journal:  Clin J Gastroenterol       Date:  2019-08-13

4.  Downregulated expression of DIXDC1 in hepatocellular carcinoma and its correlation with prognosis.

Authors:  Senjun Zhou; Jiliang Shen; Shuang Lin; Xiaolong Liu; Ming Xu; Liang Shi; Xianfa Wang; Xiujun Cai
Journal:  Tumour Biol       Date:  2016-07-28

5.  Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial.

Authors:  Ning Lv; Yanan Kong; Luwen Mu; Tao Pan; Qiankun Xie; Ming Zhao
Journal:  Eur Radiol       Date:  2016-01-22       Impact factor: 5.315

Review 6.  Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma.

Authors:  Renumathy Dhanasekaran; Jayant A Talwalkar
Journal:  Curr Gastroenterol Rep       Date:  2015-09

7.  Intratumoral γδ T-Cell Infiltrates, Chemokine (C-C Motif) Ligand 4/Chemokine (C-C Motif) Ligand 5 Protein Expression and Survival in Patients With Hepatocellular Carcinoma.

Authors:  Na Zhao; Hien Dang; Lichun Ma; Sean P Martin; Marshonna Forgues; Kris Ylaya; Stephen M Hewitt; Xin Wei Wang
Journal:  Hepatology       Date:  2021-03       Impact factor: 17.298

8.  The NKD1/Rac1 feedback loop regulates the invasion and migration ability of hepatocarcinoma cells.

Authors:  Jie Li; Sheng Zhang; Qing Hu; Kang Zhang; Jianbin Jin; Xuqing Zheng; Zhenyu Yin; Xiaomin Wang
Journal:  Sci Rep       Date:  2016-05-27       Impact factor: 4.379

9.  Combining Preoperative and Postoperative Inflammatory Indicators Can Better Predict the Recurrence of Hepatocellular Carcinoma After Partial Hepatectomy.

Authors:  Meilong Wu; Shizhong Yang; Xiaobin Feng; Chengquan Li; Xiangchen Liu; Zhenyu Zhang; Ying Xiao; Chuchu Liu; Jiahong Dong
Journal:  J Inflamm Res       Date:  2021-07-13

10.  Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression.

Authors:  Xuening Ji; Shi Jin; Xiaotong Qu; Kejun Li; Hongjiang Wang; Hui He; Fuchao Guo; Lei Dong
Journal:  BMC Cancer       Date:  2015-10-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.